Sentinel lymph node biopsy in breast cancer after neoadjuvant therapy using a magnetic tracer versus standard technique: A multicentre comparative non-inferiority study (IMAGINE-II)
Authors:
- Julia Giménez-ClimentJGJulia Giménez-Climent
- Caridad Marín-HernándezCMCaridad Marín-Hernández
- Carlos A. Fuster-DianaCFCarlos A. Fuster-Diana
- Jose A. Torró-RichartJTJose A. Torró-Richart
- Joaquin Navarro-CeciliaJNJoaquin Navarro-Cecilia
Open Access
- 1 September 2021
- journal article
- research article
- Published by Wolters Kluwer Health in International Journal of Surgery Open
- Vol. 35
Abstract
: Introduction: Previous studies have shown that a magnetic tracer technique using superparamagnetic iron oxide (SPIO) and a manual magnetometer (Sentimag, SM) is as effective as the standard technique using a radioisotope injection and a gamma probe (GP) for the detection of sentinel lymph nodes (SLNs) in breast cancer (BC) patients. This study was designed to investigate the performance of SM for post-neoadjuvant (NAT) SLN biopsy in BC patients. Materials and methods: Post-NAT BC patients were recruited from five centres. Readings of SLNs were recorded in transcutaneous, intraoperative and ex vivo scenarios by both GP and SM techniques. SLNs were assessed by OSNA (One-Step Nucleic Acid Amplification). Results: A total of 89 patients were included. At the patient level, the transcutaneous and intraoperative SLN detection rate was 97.8% by both techniques. At the node level, the GP detection rate intraoperatively was lower than that of SM (93.8% vs. 99.2%), with a concordance rate of 93% (90% CI 1.25; 9.44). The ex vivo detection rate was lower for GP compared to SM both per patient 96.6% vs. 97.8%, and per node 90.6% vs. 98.4% (90% CI -2.03; 4.22 and 1.82; 13.68, respectively). Furthermore, the detection rate of pathologically positive SLNs per patient and per node was lower for GP than SM both intraoperatively and ex vivo. These results showed the non-inferiority of SM intraoperatively per node (90% CI -4.89; 20.89) and ex vivo per patient (90% CI -2.38; 29.66). Conclusion: Our study showed the non-inferiority of SM compared to GP for detecting SLNs in post-NAT BC patients. Highlights:Keywords
This publication has 25 references indexed in Scilit:
- Characteristics of Breast Carcinoma Cases With False-Negative Sentinel Lymph NodesClinical Breast Cancer, 2014
- The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Intraoperative molecular analysis of total tumor load in sentinel lymph node: a new predictor of axillary status in early breast cancer patientsBreast Cancer Research and Treatment, 2013
- Adjusted Wald Confidence Interval for a Difference of Binomial Proportions Based on Paired DataJournal of Educational and Behavioral Statistics, 2012
- Diagnosis of the sentinel lymph node in breast cancer: a reproducible molecular method: a multicentric Spanish studyHistopathology, 2011
- The feasibility and accuracy of sentinel lymph node biopsy in clinically node‐negative patients after neoadjuvant chemotherapy for breast cancer—a systematic review and meta‐analysisJournal of Surgical Oncology, 2011
- One-step Nucleic Acid Amplification for Intraoperative Detection of Lymph Node Metastasis in Breast Cancer PatientsClinical Cancer Research, 2007
- Randomized Multicenter Trial of Sentinel Node Biopsy Versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC TrialJNCI: Journal of the National Cancer Institute, 2006
- Lymphatic mapping and sentinel lymph node biopsy in early‐stage breast carcinomaCancer, 2005
- Pathobiology of preoperative chemotherapyCancer, 2002